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The analysis of the toxicity of the abnormal form of the
prion protein (PrPSc) using a cell culture model has been
centred on the toxicity of a synthetic peptide based on the
sequence of the human prion protein. The toxicity of this
peptide was reported initially by Forloni et al. [1]. Since
then a vast body of research has appeared characterising the
mechanism of toxicity of this peptide, its ability to mimic the
toxicity of PrPSc in culture [2] and its e¡ect on glial cells. The
recent article by Kunz et al. (1999) published in FEBS Letters
makes the claim that the peptide has no inherent toxicity and
that the only toxicity the authors found was due to HPLC
chemicals not removed during puri¢cation. A detailed analysis
of this paper indicates that the authors have no valid reason
for their assertion.
PrP106^126 has been demonstrated to be toxic by many
independent laboratories [1,3^8] including my own [9]. Unlike
the work of Kunz et al. these experiments were often carried
out using multiple control peptides [1] which included known
toxic peptides such as those related to the L-amyloid sequence
or those based on the sequence of human PrP but not toxic.
In many cases the secondary structure and ¢brillar nature of
the peptides was studied in parallel in order to determine what
physical qualities were necessary for the toxicity [10]. Such an
analysis is missing from the paper of Kunz et al. Even more
so, in some studies cultures of cells from PrP-de¢cient mice
were used as a control as PrP106^126 was not toxic to these
cells. If the toxicity was related to HPLC contaminants then
one would expect toxicity to be the same on both cell types.
The paper of Kunz et al. contains no such control experi-
ments. It seems unlikely that HPLC contaminants could
have been the cause of PrP106^126 toxicity in situations
where di¡erent peptides at the same concentrations prepared
with similar techniques had di¡erent toxicities [1].
The authors claim that the toxicity they report in Table 1 of
their article (Authentic HPLC) is due to HPLC contamina-
tion. However, the authors do not identify what this contam-
inant is. This should have been a relatively simple matter
given that the authors had access to mass spectroscopy tech-
niques and know the composition of their HPLC bu¡er. The
¢nding that HPLC bu¡er is toxic has no relevance to the
work of others. Most biochemists involved with peptide syn-
thesis are aware of the need to remove HPLC contaminants
and the peptides that I have used have been analysed by syn-
thesis and mass spectroscopy similar to those described by
Kunz et al. The lack of apparent toxicity of their peptide
(apparently from only two preparations) cannot be explained
by the addition of toxic chemicals to their preparations.
Despite the large number of papers quoted by the authors
on the toxicity of PrP106^126 the authors seem to have paid
little attention to their content. The methodology used in pre-
paring their peptides has not been used in most of the papers
describing this peptide. Inducing ¢bril formation and spinning
out the ¢brils using ultracentrifugation is not necessary for the
induction of a toxic nature for this peptide. Indeed, although
the authors claim to induce ¢brils there is no evidence that
there were any ¢brils in their preparations (e.g. no EM micro-
graphs). This preparation technique seems a rather odd thing
to do given that the authors then routinely ¢ltered the ¢brils
from their stock solutions as described in Section 3.3 of their
article. It has also been published that the peptide must con-
sist of a mixture of aggregated and non-aggregated material in
order to elicit a maximal toxic response [10]. This is something
the authors appear not to take into account when carrying out
their experiments. Also, although the authors con¢rm the pu-
rity of their peptide initially they do not, after their long and
complicated treatment process, con¢rm how much peptide
actually reaches their cultures. If not all the peptide forms
¢brils before ultracentrifugation then some percentage would
be lost. Also if most of the peptide does form ¢brils then it is
unlikely that any of their peptide would pass through their 0.2
Wm ¢lter. Therefore as this method was used for almost all the
experiments in their paper then it is likely that the authors
added no peptide to their cultures.
Additionally, it has been published that microglia are nec-
essary for the toxicity of PrP106^126 [3]. However, the au-
thors do not add microglia to their cultures to see if this
enhances the toxicity of their peptide, or that of their
HPLC bu¡er.
The cortical cell cultures used for the authors’ Fig. 1 appear
to have been very low density. Additionally their cultures
appear to be full of debris typical of poor and dying cultures.
The authors’ claim to have used methods used by other labo-
ratories. However, despite quoting my own work the method
they describe is not the same as the one that I used or have
continued to use either in the laboratory of Kretzschmar [3] or
in my own [9]. Indeed, a major problem with the paper is the
total lack of analysis of the cultures used. It is possible that
the cultures prepared by Kunz et al. contained no or very few
neurones. Also, as microglia are necessary for the toxicity of
PrP106^126 the authors need to show that their cultures con-
tain microglia before the toxicity of PrP106^126 can be
brought into doubt. A further point, given the low density
of the cultures, is that the majority of the experiments the
authors describe were carried out in 96 well plates. I doubt
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that the authors could produce statistically meaningful results
with such small measurements. As regards the measurements
themselves, there is no indication in the paper as to how long
exposure to the peptide was for (i.e. how many days). Many
experiments are reported as (Data not shown) or have low,
statistically minuscule, n values (i.e. 2 or 1).
The ¢nal problem with this work is that the authors do not
present all the data they have. I was contacted by the ¢rst
author during the time these experiments were being carried
out. I agreed to test their peptide for toxicity. I received their
peptide and was able to carry out a small number of experi-
ments on cerebellar cells in parallel with peptide of my own. I
used ¢ltered and un¢ltered samples of their peptide and found
that, like Kunz et al., the ¢ltered peptide was not toxic. How-
ever, the non-¢ltered peptide was toxic (see Table 1). The
toxicity was much less than that of my own peptide. Above
all else this result suggests that there was a problem in the
methodology employed by Kunz et al. in assessing the toxicity
of PrP106^126. Clearly, the ability to ¢lter out the toxicity of
a peptide solution with a 0.2 Wm ¢lter indicates that the tox-
icity of their peptide was not due to an HPLC contaminant.
In summary, Kunz et al. have not demonstrated that
PrP106^126 is not toxic. Their paper lacks the kinds of con-
trols and assays necessary to reach such a conclusion. There
are many possible explanations for their results, none of
which have been explored by the authors, the simplest of
which could be that insu⁄cient peptide, in the right confor-
mation, reaches their cells for a toxic e¡ect.
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Table 1
Peptide toxicity to cerebellar cell cultures determined by MTT assay
% Untreated control value
No peptide 100 þ 2
PrP106^126 53 þ 4
Control PrP106^126 (scrambled) 98 þ 2
Kunz et al. PrP106^126 78 þ 3
Kunz et al. PrP106^126 (¢ltered) 98 þ 3
Peptides were applied for 5 days at 80 WM. The methods used were
as previously described [3]. Mean and S.E.M. for three experiments
with all peptides in each experiment (three determinations each).
The experiments were done in 24 well plates.
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